Caffeine and progression of parkinson disease

Clinical Neuropharmacology

Volumn 31, Issue 4, 2008, Pages 189-196

  Simon, David K ^a   Swearingen, Christopher J ^b   Hauser, Robert A ^c   Trugman, Joel M ^d   Aminoff, Michael J ^e   Singer, Carlos ^f   Truong, Daniel ^g   Tilley, Barbara C ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g Parkinson's and Movement Disorder Institute   (United States)

Author keywords

Adenosine A2A receptor; Coffee; Disease modifying; Neuroprotection

Indexed keywords

CAFFEINE; CREATINE; GPI 1485; MINOCYCLINE; PLACEBO; ANTIINFECTIVE AGENT; CENTRAL STIMULANT AGENT;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR ACTIVITY; MULTICENTER STUDY; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SECONDARY ANALYSIS; SYMPTOM; UNIFIED PARKINSON DISEASE RATING SCALE; ADULT; BEVERAGE; DOSE RESPONSE; PATHOPHYSIOLOGY; QUESTIONNAIRE;

ADULT; ANTI-BACTERIAL AGENTS; BEVERAGES; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CREATINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MINOCYCLINE; PARKINSON DISEASE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 53449095363     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31815a3f03     Document Type: Article

References (19)

1. Benedetti MD, Bower JH, Maraganore DM, et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 2000;55(9):1350-1358.
2. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283: 2674-2679.
3. Tan EK, Tan C, Fook-Chong SM, et al. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci 2003;216:163-167.
4. Ascherio A, Zhang SM, Hernan MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56-63.
5. Evans AH, Lawrence AD, Potts J, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:317-321.
6. Schwarzschild MA, Xu K, Oztas E, et al. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology 2003;61(11 Suppl 6): S55-S61.
7. Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol Ther 2005;105(3): 267-310.
8. Hauser RA, Schwarzschild MA. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging 2005;22:471-482.
9. Hauser RA, Hubble JP, Truong DD. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003;61: 297-303.
10. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-671.
11. The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-28.
12. Swearingen CJ. Estimating Caffeine Usage in Two Futility Clinical Trials in Parkinson's Disease [master's thesis]. Charleston, SC: Medical University of South Carolina; 2006.
13. Elm JJ, Goetz CG, Ravina B, et al. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol 2005;57(2):197-203.
14. Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266:93-98.
15. Schwarzschild MA, Chen JF, Tennis M, et al. Relating caffeine consumption to Parkinson's disease progression and dyskinesias development. Mov Disord 2003;18(9):1082-1083. Abstract.
16. Fredholm BB, Battig K, Holmen J, et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51:83-133.
17. Schwarzschild MA, Chen JF, Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology 2002;58(8): 1154-1160.
18. Hespel P, Op't Eijnde B, Van Leemputte M. Opposite actions of caffeine and creatine on muscle relaxation time in humans. J Appl Physiol 2002; 92:513-518.
19. Vandenberghe K, Gillis N, Van Leemputte M, et al. Caffeine counteracts the ergogenic action of muscle creatine loading. J Appl Physiol 1996;80: 452-457.